DPR & CMA Data on Pharmaceutical manufacturing plant (oncology drugs manufacturing & packaging, injectable drugs manufacturing & packaging, i.v. fluids, tablet, capsules, syrups, ointments etc.)

The project revolves around the establishment of a state-of-the-art pharmaceutical manufacturing plant focused primarily on oncology drugs, injectable medications, intravenous fluids, tablets, capsules, syrups, and ointments. This facility will be equipped with advanced technology and follow stringent regulatory guidelines to ensure high-quality production standards that align with the needs of the healthcare market. The demand for oncology drugs is on the rise due to the increasing prevalence of cancer globally, creating an essential need for reliable suppliers. The plant will also emphasize the manufacture of injectable drugs and IV fluids, which are critical in various therapeutic areas, especially in acute care settings. With the capability to produce a wide range of dosage forms, the plant aims to cater to both domestic and international markets while adhering to the Good Manufacturing Practices (GMP). The operational design focuses on flexibility, allowing for the efficient adaptation to changing market demands. Furthermore, with a commitment to sustainability and innovation, the plant will contribute to the advancement of pharmaceutical sciences and improve patient outcomes by providing effective treatment options. Overall, this project positions itself strategically within the pharmaceutical landscape to exploit growth opportunities in a rapidly evolving industry.

• Increasing prevalence of cancer and demand for oncology products globally.
• Rising acceptance of injectable drugs in outpatient care.
• Growing market for IV fluids due to increased surgical procedures and hospitalizations.
• Expansion of generic drug market leading to cost-effective treatment options.
• Emergence of personalized medicine driving the need for diverse formulations.

Total capital investment ranges from ₹1,500,000 to ₹71,500,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.

At the larger investment scale, the expected break-even is approximately approx. 5 years at approximately 82.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.

• Active pharmaceutical ingredients (APIs)
• Excipients for tablets and capsules
• Liquid ingredients for syrups and IV fluids
• Packaging materials (vials, blister packs, bottles)
• Aseptic processing materials for injectables
• Stabilizers and preservatives for ointments

• Advanced manufacturing technology ensuring high product quality.
• Diverse product portfolio catering to multiple therapeutic areas.
• Strong compliance with regulatory standards enhancing credibility.
• Experienced workforce contributing to effective operations.